Taiho Ventures, the strategic corporate venture capital arm of Taiho Pharmaceutical, Co., Ltd., increased its investment pool by US$250m from the initial US$50m to US$300m.
A subsidiary of Otsuka Holdings Co., Ltd., Taiho Pharmaceutical is a Japanese specialty pharma focusing on oncology, allergy and immunology, and urology.
Led by Sakae Asanuma, CFA, President, Toshiyasu Shimomura, Phd., Investmente Director and Seiji Miyahara, Phd., Associate Investmente Director, Taiho Ventures is actively searching for opportunities around the world to invest in startup companies that conduct innovative first-in-class drug discovery and establish unique platform technologies, primarily in the oncology field.
Since its inception in 2016, Taiho Ventures has built an innovative investment portfolio that includes:
– Arcus Biosciences,
– PACT Pharma,
– Harpoon Therapeutics,
– Storm Therapeutics,
– ORIC Pharmaceuticals, and
– Quentis Therapeutics.
The CVC arm is looking at early-stage preclinical oncology companies as well as platform technology companies for its core therapeutic areas. It will review the wide variety of modalities for both biologics and small molecules and will consider the option type of investments and spin-outs, in addition to the pure equity investments.
Taiho Ventures is based in Menlo Park, CA.
FinSMEs
16/10/2018